Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free THAR Stock Alerts

Tharimmune (THAR) Financials

Tharimmune logo
$2.27 -0.11 (-4.62%)
As of 07/13/2026
Compare
Annual Income Statements for Tharimmune

Annual Income Statements for Tharimmune

This table shows Tharimmune's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.42 -2.21 -8.47 -9.32 -12 -36
Consolidated Net Income / (Loss)		 -2.42 -2.21 -8.47 -9.32 -12 -36
Net Income / (Loss) Continuing Operations		 -2.42 -2.21 -8.47 -9.32 -12 -36
Total Pre-Tax Income 		-2.42 -2.21 -8.47 -9.32 -12 -42
Total Operating Income		 -1.81 -3.21 -6.88 -9.46 -12 -20
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 1.81 3.21 6.88 9.46 12 20
Selling, General & Admin Expense		 0.67 1.37 4.60 5.90 6.04 17
Research & Development Expense		 1.14 1.84 2.28 3.56 6.39 3.07
Total Other Income / (Expense), net		 -0.61 1.00 -1.59 0.14 0.24 -22
Interest Expense		 0.25 0.83 1.59 0.02 0.01 0.03
Interest & Investment Income		 - - 0.00 0.15 0.25 0.04
Other Income / (Expense), net		 -0.36 1.83 - - - -22
Income Tax Expense		 - - - - 0.00 -6.19
Basic Earnings per Share		 ($0.38) ($0.35) ($18.72) ($107.02) ($9.41) ($1.12)
Weighted Average Basic Shares Outstanding		 6.35M 6.36M 452.69K 87.08K 1.30M 32.05M
Diluted Earnings per Share		 ($0.38) - ($18.72) ($107.02) ($9.41) ($1.12)
Weighted Average Diluted Shares Outstanding		 6.35M 6.36M 452.69K 87.08K 1.30M 32.05M
Weighted Average Basic & Diluted Shares Outstanding		 6.35M 6.36M 11.51M 11.74M 2.11M 56.66M

Quarterly Income Statements for Tharimmune

This table shows Tharimmune's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.82 -2.47 -2.26 -2.33 -3.80 -3.82 -2.54 -1.86 -2.10 -29 -47
Consolidated Net Income / (Loss)		 -1.82 -2.47 -2.26 -2.33 -3.80 -3.82 -2.54 -1.86 -2.10 -29 -47
Net Income / (Loss) Continuing Operations		 -1.82 -2.47 -2.26 -2.33 -3.80 -3.82 -2.54 -1.86 -2.10 -29 -47
Total Pre-Tax Income 		-1.82 -2.47 -2.26 -2.33 -3.80 -3.82 -2.54 -1.86 -2.10 -36 -52
Total Operating Income		 -1.85 -2.53 -2.35 -2.37 -3.87 -3.85 -2.55 -1.85 -2.09 -14 -37
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 1.85 2.53 2.35 2.37 3.87 3.85 2.55 1.85 2.09 14 37
Selling, General & Admin Expense		 1.36 1.54 1.32 1.37 1.58 1.76 1.95 1.30 1.82 12 37
Research & Development Expense		 0.49 0.99 1.03 1.00 2.28 2.09 0.59 0.55 0.28 1.66 0.27
Total Other Income / (Expense), net		 0.02 0.06 0.09 0.05 0.07 0.03 0.00 -0.00 -0.01 -22 -15
Interest Expense		 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.00
Interest & Investment Income		 0.03 0.06 0.10 0.05 0.07 0.03 0.01 0.00 0.00 0.02 0.32
Other Income / (Expense), net		 - - - - - - - - - - -15
Income Tax Expense		 - - - - - - 0.00 - - - -4.22
Basic Earnings per Share		 ($39.42) ($28.41) ($2.55) ($2.42) ($2.45) ($2.95) ($0.99) ($0.64) ($0.34) ($0.92) ($0.23)
Weighted Average Basic Shares Outstanding		 46.17K 87.08K 885.68K 962.15K 1.55M 1.30M 2.57M 2.88M 6.24M 32.05M 207.71M
Diluted Earnings per Share		 ($39.42) ($28.41) ($2.55) ($2.42) ($2.45) ($2.95) ($0.99) ($0.64) ($0.34) ($0.92) ($0.23)
Weighted Average Diluted Shares Outstanding		 46.17K 87.08K 885.68K 962.15K 1.55M 1.30M 2.57M 2.88M 6.24M 32.05M 207.71M
Weighted Average Basic & Diluted Shares Outstanding		 17.51M 11.74M 11.79M 1.15M 1.49M 2.11M 2.66M 4.64M 35.04M 56.66M 69.80M

Annual Cash Flow Statements for Tharimmune

This table details how cash moves in and out of Tharimmune's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.15 -0.19 6.51 4.42 -7.38 13
Net Cash From Operating Activities		 -1.08 -1.09 -6.56 -7.30 -11 -16
Net Cash From Continuing Operating Activities		 -1.08 -1.09 -6.56 -7.30 -11 -16
Net Income / (Loss) Continuing Operations		 -2.42 -2.21 -8.47 -9.32 -12 -36
Consolidated Net Income / (Loss)		 -2.42 -2.21 -8.47 -9.32 -12 -36
Non-Cash Adjustments To Reconcile Net Income		 0.89 -0.43 0.72 1.18 0.73 19
Changes in Operating Assets and Liabilities, net		 0.31 0.88 -0.38 0.84 0.56 0.99
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 0.00 -78
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 0.00 -78
Other Investing Activities, net		 - - - - 0.00 -78
Net Cash From Financing Activities		 1.23 0.90 13 12 3.53 107
Net Cash From Continuing Financing Activities		 1.23 0.90 13 12 3.53 107
Repayment of Debt		 - 0.00 -0.14 - -0.66 -10
Issuance of Common Equity		 - 0.00 14 12 4.19 116
Other Financing Activities, net		 0.00 0.00 0.02 0.00 0.00 1.71
Cash Interest Paid		 - - 0.02 0.02 0.01 0.03

Quarterly Cash Flow Statements for Tharimmune

This table details how cash moves in and out of Tharimmune's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.21 8.25 -2.51 -0.53 -3.12 -1.21 -2.48 1.17 5.37 9.42 24
Net Cash From Operating Activities		 -0.91 -1.42 -2.83 -2.18 -2.86 -3.03 -2.69 -1.14 -1.86 -10 -7.64
Net Cash From Continuing Operating Activities		 -0.91 -1.42 -2.83 -2.18 -2.86 -3.03 -2.69 -1.15 -1.85 -10 -7.64
Net Income / (Loss) Continuing Operations		 -1.82 -2.47 -2.26 -2.33 -3.80 -3.82 -2.54 -1.86 -2.10 -29 -47
Consolidated Net Income / (Loss)		 -1.82 -2.47 -2.26 -2.33 -3.80 -3.82 -2.54 -1.86 -2.10 -29 -47
Non-Cash Adjustments To Reconcile Net Income		 0.41 0.27 0.17 0.15 0.19 0.21 0.22 0.56 0.63 17 43
Changes in Operating Assets and Liabilities, net		 0.50 0.79 -0.74 -0.01 0.74 0.58 -0.37 0.14 -0.37 1.58 -3.34
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - - -78 -55
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - - -78 -55
Other Investing Activities, net		 - - - - - - 0.00 - - - -55
Net Cash From Financing Activities		 -0.31 9.66 0.32 1.65 -0.26 1.82 0.21 2.31 7.22 97 87
Net Cash From Continuing Financing Activities		 -0.31 9.66 0.32 1.65 -0.26 1.82 0.21 2.31 7.22 97 87
Repayment of Debt		 - - 0.00 -0.32 -0.14 -0.20 -0.04 -0.29 -1.04 -8.83 -3.56
Issuance of Common Equity		 -0.39 9.98 - - - 2.10 0.00 - 8.32 105 90
Other Financing Activities, net		 -0.24 -0.08 0.32 -0.12 -0.12 -0.08 0.25 -0.16 -0.05 1.67 0.09
Cash Interest Paid		 - - 0.00 - - - 0.01 - - - 0.00

Annual Balance Sheets for Tharimmune

This table presents Tharimmune's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.29 0.62 6.69 11 3.72 519
Total Current Assets		 0.29 0.62 6.69 11 3.72 17
Cash & Equivalents		 0.19 0.00 6.51 11 3.56 17
Prepaid Expenses		 0.10 0.07 0.18 0.01 0.05 0.35
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.00 502
Other Noncurrent Operating Assets		 - - - - 0.00 502
Total Liabilities & Shareholders' Equity		 0.29 0.62 6.69 11 3.72 519
Total Liabilities		 4.01 5.31 1.14 1.82 2.41 121
Total Current Liabilities		 2.73 4.53 1.14 1.82 2.41 3.29
Accounts Payable		 0.71 1.66 0.95 0.91 1.09 1.09
Accrued Expenses		 0.05 0.32 - 0.91 1.32 2.20
Total Noncurrent Liabilities		 1.29 0.77 0.00 0.00 0.00 118
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - 118
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -3.72 -4.68 5.54 9.13 1.31 398
Total Preferred & Common Equity		 -3.72 -4.68 5.54 9.13 1.31 398
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -3.72 -4.68 5.54 9.13 1.31 398
Common Stock		 0.99 2.23 21 34 38 471
Retained Earnings		 -4.70 -6.91 -15 -25 -37 -73
Treasury Stock		 - 0.00 -0.07 -0.07 -0.07 -0.07

Quarterly Balance Sheets for Tharimmune

This table presents Tharimmune's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 3.17 8.89 8.26 5.25 1.66 2.53 7.70 585
Total Current Assets		 3.17 8.89 8.26 5.25 1.66 2.53 7.70 43
Cash & Equivalents		 2.69 8.43 7.90 4.77 1.08 2.24 7.61 42
Prepaid Expenses		 0.41 0.46 0.30 0.48 0.47 0.20 0.09 1.55
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 542
Other Noncurrent Operating Assets		 - - - - - - - 542
Total Liabilities & Shareholders' Equity		 3.17 8.89 8.26 5.25 1.66 2.53 7.70 585
Total Liabilities		 1.41 1.84 1.56 2.23 2.48 2.16 1.54 115
Total Current Liabilities		 1.41 1.84 1.56 2.23 2.48 2.16 1.54 1.14
Accounts Payable		 1.14 0.99 0.78 0.78 0.84 0.77 0.66 0.40
Accrued Expenses		 - - 0.58 1.37 1.12 1.06 0.69 0.74
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 114
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - 114
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.76 7.05 6.69 3.02 -0.81 0.37 6.15 470
Total Preferred & Common Equity		 1.76 7.05 6.69 3.02 -0.81 0.37 6.15 470
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1.76 7.05 6.69 3.02 -0.81 0.37 6.15 470
Common Stock		 24 34 36 36 39 42 50 590
Retained Earnings		 -22 -27 -29 -33 -39 -41 -43 -120
Treasury Stock		 -0.07 -0.07 -0.07 -0.07 -0.07 -0.07 -0.07 -0.07

Annual Metrics And Ratios for Tharimmune

This table displays calculated financial ratios and metrics derived from Tharimmune's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 11,529,861.00 17,511,839.00 1,486,037.00 35,044,812.00
DEI Adjusted Shares Outstanding		 0.00 0.00 30,746.00 46,698.00 1,486,037.00 35,044,812.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -275.59 -199.56 -8.21 -1.02
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 65.01% -649.57% -77.97% -31.50% -238.73%
EBIT Growth		 0.00% 36.64% -400.37% -37.39% -31.50% -238.73%
NOPAT Growth		 0.00% -77.40% -114.52% -37.39% -31.50% -61.71%
Net Income Growth		 0.00% 8.72% -283.99% -9.98% -30.89% -194.45%
EPS Growth		 0.00% 0.00% 0.00% -9.98% 91.21% 88.10%
Operating Cash Flow Growth		 0.00% -0.72% -503.73% -11.32% -49.34% -47.94%
Free Cash Flow Firm Growth		 0.00% 0.00% -238.31% 12.44% -47.66% -4,711.31%
Invested Capital Growth		 0.00% -18.04% 66.88% -132.35% -24.82% 17,015.66%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -54.60% -8.80% -11.84% -307.36%
EBIT Q/Q Growth		 0.00% 0.00% -31.91% -8.80% -11.84% -307.36%
NOPAT Q/Q Growth		 0.00% 0.00% -31.91% -8.80% -11.84% -94.47%
Net Income Q/Q Growth		 0.00% 0.00% -99.19% -8.21% -12.41% -248.05%
EPS Q/Q Growth		 0.00% 0.00% -99.19% -8.21% -34.24% 32.12%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -15.60% -7.71% -17.43% -84.95%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 3.97% -22.00% -5,059.02%
Invested Capital Q/Q Growth		 0.00% 0.00% -61.50% -143.18% -28.18% 29,526.32%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 85.30%
Interest Burden Percent		 111.36% 160.44% 123.12% 98.56% 98.10% 99.97%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 65.03% 52.52% -1,973.37% -127.01% -233.69% -17.99%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -104.29%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 65.03% 52.52% -1,973.37% -127.01% -233.69% -17.99%
Return on Equity Simple (ROE_SIMPLE)		 65.03% 47.10% -152.84% -102.06% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.27 -2.25 -4.82 -6.62 -8.70 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 66.50% -1.91% -183.74% -31.30% -48.21% -212.14%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -72.48% -665.60% -3.54%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.17 -1.38 -6.88 -9.46 -12 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.03 -0.71 -5.31 -9.46 -12 -42
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.81 0.04 2.31 0.27
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.81 0.04 2.31 0.27
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.23
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 -0.50 -0.46 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 -0.35 -0.17 0.00 0.00 0.00 0.00
Financial Leverage		 -0.47 -0.48 -4.63 -1.18 -1.39 -0.05
Leverage Ratio		 -0.08 -0.11 8.51 1.20 1.41 1.31
Compound Leverage Factor		 -0.09 -0.18 10.48 1.18 1.38 1.31
Debt to Total Capital		 -99.10% -85.95% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -30.18% -55.27% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -68.93% -30.68% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 199.10% 185.95% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.91 -3.06 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -0.82 -3.05 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.64 -1.09 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.46 -0.96 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -1.31 -0.96 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -1.02 -0.34 0.00 0.00 0.00 0.00
Altman Z-Score		 -54.29 -28.72 -3.27 -4.89 -23.74 0.09
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.11 0.14 5.84 6.03 1.54 5.29
Quick Ratio		 0.07 0.00 5.69 6.02 1.47 5.18
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -1.89 -6.39 -5.59 -8.26 -397
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -2.27 -4.01 -338.75 -603.33 -14,013.73
Operating Cash Flow to Interest Expense		 -4.37 -1.31 -4.12 -442.30 -796.70 -569.00
Operating Cash Flow Less CapEx to Interest Expense		 -4.37 -1.31 -4.12 -442.30 -796.70 -569.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -1.99 -2.34 -0.78 -1.80 -2.25 381
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.36 1.57 -1.03 -0.45 383
Enterprise Value (EV)		 17 17 -2.02 -11 -0.54 89
Market Capitalization		 15 15 4.49 0.36 3.02 106
Book Value per Share		 ($0.59) ($0.74) $0.48 $0.52 $0.88 $11.35
Tangible Book Value per Share		 ($0.59) ($0.74) $0.48 $0.52 $0.88 $11.35
Total Capital		 -1.87 -2.52 5.54 9.13 1.31 398
Total Debt		 1.85 2.17 0.00 0.00 0.00 0.00
Total Long-Term Debt		 1.29 0.77 0.00 0.00 0.00 0.00
Net Debt		 1.66 2.16 -6.51 -11 -3.56 -17
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.06 -2.52 -0.97 -1.80 -2.25 -2.93
Debt-free Net Working Capital (DFNWC)		 -1.87 -2.52 5.54 9.13 1.31 14
Net Working Capital (NWC)		 -2.43 -3.91 5.54 9.13 1.31 14
Net Nonoperating Expense (NNE)		 1.15 -0.04 3.66 2.70 3.49 22
Net Nonoperating Obligations (NNO)		 1.73 2.34 -6.32 -11 -3.56 -17
Total Depreciation and Amortization (D&A)		 0.15 0.67 1.57 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($131.25) ($281.25) ($107.10) ($9.41) ($1.12)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 30.31K 30.18K 87.03K 1.30M 32.05M
Adjusted Diluted Earnings per Share		 $0.00 ($131.25) $0.00 ($107.10) ($9.41) ($1.12)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 30.31K 30.70K 87.03K 1.30M 32.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($131.25) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 16.95K 30.70K 782.65K 2.11M 56.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.27 -2.25 -4.82 -6.62 -8.70 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -8.81 -1.65 -4.32 -572.87 -908.64 -1,485.85
NOPAT to Interest Expense		 -5.13 -2.70 -3.03 -401.01 -636.05 -496.53
EBIT Less CapEx to Interest Expense		 -8.81 -1.65 -4.32 -572.87 -908.64 -1,485.85
NOPAT Less CapEx to Interest Expense		 -5.13 -2.70 -3.03 -401.01 -636.05 -496.53
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -8.12% -6.98% -5.57% 0.00% 0.00%

Quarterly Metrics And Ratios for Tharimmune

This table displays calculated financial ratios and metrics derived from Tharimmune's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 17,532,637.00 17,511,839.00 17,511,839.00 11,789,676.00 1,148,760.00 1,486,037.00 2,108,753.00 2,660,727.00 4,635,251.00 35,044,812.00 56,656,271.00
DEI Adjusted Shares Outstanding		 46,754.00 46,698.00 46,698.00 785,978.00 1,148,760.00 1,486,037.00 2,108,753.00 2,660,727.00 4,635,251.00 35,044,812.00 56,656,271.00
DEI Earnings Per Adjusted Shares Outstanding		 -38.93 -52.97 -48.31 -2.96 -3.30 -2.57 -1.21 -0.70 -0.45 -0.84 -0.84
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 13.27% -43.29% 13.52% -0.37% -109.51% -52.00% -8.49% 22.01% 45.84% -253.86% -1,937.23%
EBIT Growth		 13.27% -43.29% 13.52% -0.37% -109.51% -52.00% -8.49% 22.01% 45.84% -253.86% -1,937.23%
NOPAT Growth		 13.27% -43.29% 13.52% -0.37% -109.51% -52.00% -8.49% 22.01% 45.84% -253.86% -1,347.71%
Net Income Growth		 14.45% -40.04% 16.08% 0.51% -108.55% -54.44% -12.66% 20.21% 44.63% -669.98% -1,762.66%
EPS Growth		 14.45% -40.04% 16.08% 95.35% 93.78% 89.62% 61.18% 73.55% 86.12% 68.81% 76.77%
Operating Cash Flow Growth		 41.32% -58.56% 18.46% -44.23% -215.07% -114.33% 4.82% 47.57% 35.22% -244.19% -183.94%
Free Cash Flow Firm Growth		 -2.18% 73.46% 64.06% 7.93% -64.11% -201.73% -10.33% 28.84% -14.00% -17,387.12% -44,845.60%
Invested Capital Growth		 -54.31% -132.35% -573.87% -56.69% -136.80% -24.82% -90.41% -35.19% 26.32% 17,015.66% 26,550.21%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 21.97% -37.18% 7.26% -1.11% -62.87% 0.47% 33.81% 27.31% -13.10% -550.31% -281.07%
EBIT Q/Q Growth		 21.97% -37.18% 7.26% -1.11% -62.87% 0.47% 33.81% 27.31% -13.10% -550.31% -281.07%
NOPAT Q/Q Growth		 21.97% -37.18% 7.26% -1.11% -62.87% 0.47% 33.81% 27.31% -13.10% -550.31% -170.80%
Net Income Q/Q Growth		 22.11% -35.91% 8.80% -3.06% -63.26% -0.65% 33.47% 27.01% -13.30% -1,299.61% -60.94%
EPS Q/Q Growth		 22.11% -35.91% 8.80% 5.10% -1.24% -20.41% 66.44% 35.35% 46.88% -170.59% 75.00%
Operating Cash Flow Q/Q Growth		 39.84% -55.72% -99.60% 22.86% -31.41% -5.93% 11.36% 57.51% -62.37% -462.84% 26.88%
Free Cash Flow Firm Q/Q Growth		 22.65% 27.78% -23.48% -33.48% -37.87% -32.79% 54.85% 13.91% -120.87% -20,269.12% -16.05%
Invested Capital Q/Q Growth		 3.29% -143.18% 52.86% -41.34% -46.16% -28.18% 28.09% -0.36% 20.34% 29,526.32% 12.44%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 82.62% 91.82%
Interest Burden Percent		 98.65% 97.73% 96.11% 97.96% 98.20% 99.30% 99.81% 100.22% 100.39% 261.52% 99.39%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -194.12% -127.01% -173.40% -181.81% -454.53% -233.69% -400.44% -340.26% -225.01% -17.99% -34.42%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -104.29% -109.27%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -194.12% -127.01% -173.40% -181.81% -454.53% -233.69% -400.44% -340.26% -225.01% -17.99% -34.42%
Return on Equity Simple (ROE_SIMPLE)		 -490.16% 0.00% -126.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.29 -1.77 -1.64 -1.66 -2.71 -2.69 -1.78 -1.30 -1.47 -9.53 -26
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -10.47% -8.14% -10.92% -11.31% -29.97% -15.56% -17.44% -11.31% -10.41% -193.15% -101.73%
Return On Investment Capital (ROIC_SIMPLE)		 - -19.40% -23.31% -24.82% -89.67% -205.96% 328.17% -209.99% -23.20% -2.40% -5.49%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.85 -2.53 -2.35 -2.37 -3.87 -3.85 -2.55 -1.85 -2.09 -14 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.85 -2.53 -2.35 -2.37 -3.87 -3.85 -2.55 -1.85 -2.09 -14 -52
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.00 0.04 0.04 0.41 0.94 2.31 0.00 14.05 2.14 0.27 0.39
Price to Tangible Book Value (P/TBV)		 2.00 0.04 0.04 0.41 0.94 2.31 0.00 14.05 2.14 0.27 0.39
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.23 0.34
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 -0.33 0.68 0.03 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.14 -1.18 -1.10 -1.20 -1.52 -1.39 -1.40 -1.40 -1.33 -0.05 -0.09
Leverage Ratio		 1.24 1.20 1.33 1.32 1.76 1.41 1.69 1.53 1.41 1.31 1.25
Compound Leverage Factor		 1.22 1.17 1.28 1.29 1.73 1.40 1.69 1.53 1.42 3.43 1.24
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -49.97% 40.47% 2.55% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -49.97% 40.47% 2.55% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 149.97% 59.53% 97.45% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.02 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.16 0.72 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.03 -0.02 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.24 1.03 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -9.59 -2.80 -4.07 -3.88 -9.79 -16.12 -38.19 -23.66 -2.72 0.28 0.47
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.25 6.03 4.84 5.28 2.35 1.54 0.67 1.17 4.98 5.29 37.75
Quick Ratio		 1.91 6.02 4.59 5.05 2.14 1.47 0.43 1.04 4.93 5.18 36.39
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.03 -0.74 -0.92 -1.23 -1.69 -2.25 -1.01 -0.87 -1.93 -393 -456
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -294.75 -2,102.30 -195.52 -235.11 -562.00 -2,962.42 -119.69 -141.67 -199.81 -96,599.04 0.00
Operating Cash Flow to Interest Expense		 -260.00 -3,998.38 -601.10 -417.73 -951.76 -4,002.17 -317.44 -185.45 -192.29 -2,568.66 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -260.00 -3,998.38 -601.10 -417.73 -951.76 -4,002.17 -317.44 -185.45 -192.29 -2,568.66 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.74 -1.80 -0.85 -1.20 -1.76 -2.25 -1.62 -1.62 -1.29 381 428
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.26 -1.03 -0.72 -0.43 -1.01 -0.45 -0.77 -0.42 0.46 383 430
Enterprise Value (EV)		 0.82 -11 -8.13 -5.12 -1.93 -0.54 2.06 3.17 5.71 89 144
Market Capitalization		 3.51 0.36 0.30 2.77 2.85 3.02 2.87 5.16 13 106 185
Book Value per Share		 $0.10 $0.52 $7.96 $0.57 $2.63 $0.88 ($0.39) $0.14 $1.33 $11.35 $13.41
Tangible Book Value per Share		 $0.10 $0.52 $7.96 $0.57 $2.63 $0.88 ($0.39) $0.14 $1.33 $11.35 $13.41
Total Capital		 1.76 9.13 7.05 6.69 3.02 1.31 -0.54 0.62 6.32 398 470
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.27 0.25 0.16 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -2.69 -11 -8.43 -7.90 -4.77 -3.56 -0.80 -1.99 -7.45 -17 -42
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.93 -1.80 -1.38 -1.20 -1.76 -2.25 -1.62 -1.62 -1.29 -2.93 0.41
Debt-free Net Working Capital (DFNWC)		 1.76 9.13 7.05 6.69 3.02 1.31 -0.54 0.62 6.32 14 42
Net Working Capital (NWC)		 1.76 9.13 7.05 6.69 3.02 1.31 -0.81 0.37 6.15 14 42
Net Nonoperating Expense (NNE)		 0.53 0.70 0.61 0.66 1.09 1.13 0.76 0.56 0.64 20 22
Net Nonoperating Obligations (NNO)		 -2.50 -11 -7.90 -7.90 -4.77 -3.56 -0.80 -1.99 -7.45 -17 -42
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($41.25) ($426.15) ($2.85) ($2.42) ($2.45) ($2.95) ($0.99) ($0.64) ($0.34) ($0.92) ($0.23)
Adjusted Weighted Average Basic Shares Outstanding		 46.12K 5.81K 783.85K 962.15K 1.55M 1.30M 2.57M 2.88M 6.24M 32.05M 207.71M
Adjusted Diluted Earnings per Share		 ($41.25) ($426.15) ($2.85) ($2.42) ($2.45) ($2.95) ($0.99) ($0.64) ($0.34) ($0.92) ($0.23)
Adjusted Weighted Average Diluted Shares Outstanding		 46.12K 5.81K 783.85K 962.15K 1.55M 1.30M 2.57M 2.88M 6.24M 32.05M 207.71M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($426.15) $0.00 $0.00 $0.00 ($2.95) $0.00 $0.00 $0.00 ($0.92) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 46.70K 782.65K 785.98K 1.15M 1.49M 2.11M 2.66M 4.64M 35.04M 56.66M 69.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.29 -1.77 -1.64 -1.66 -2.71 -2.69 -1.78 -1.30 -1.47 -9.53 -26
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -527.77 -7,150.16 -499.43 -454.95 -1,284.67 -5,075.81 -300.63 -300.46 -217.00 -3,349.24 0.00
NOPAT to Interest Expense		 -369.44 -5,005.11 -349.60 -318.46 -899.27 -3,553.07 -210.44 -210.32 -151.90 -2,344.47 0.00
EBIT Less CapEx to Interest Expense		 -527.77 -7,150.16 -499.43 -454.95 -1,284.67 -5,075.81 -300.63 -300.46 -217.00 -3,349.24 0.00
NOPAT Less CapEx to Interest Expense		 -369.44 -5,005.11 -349.60 -318.46 -899.27 -3,553.07 -210.44 -210.32 -151.90 -2,344.47 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -4.08% -5.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Hillstream BioPharma (NASDAQ: CNTN) remains a highly unprofitable, cash-burning development-stage biotech, but Q1 2026 showed a mixed picture: operating losses widened sharply while the company raised substantial equity capital and finished the quarter with a much stronger cash balance.

For retail investors, the key takeaway is that CNTN is still not generating revenue and is relying on financing to fund operations. The balance sheet improved materially in terms of cash, but dilution remains a major overhang, and the business is still producing large losses.

  • Cash increased sharply in Q1 2026. Cash and equivalents rose to about $41.5 million from $7.6 million at the end of Q3 2025, helped by financing activity and a positive net change in cash of $24.5 million.
  • Equity financing provided a major cash infusion. CNTN raised about $90.4 million through issuance of common equity in Q1 2026, which significantly boosted liquidity.
  • Current liabilities remain low relative to assets. Total current liabilities were only about $1.1 million versus $43.1 million in current assets at Q1 2026, giving the company a strong near-term liquidity profile.
  • Operating cash burn improved versus Q4 2025. Net cash used in operating activities was about $7.6 million in Q1 2026, better than the roughly $10.4 million used in Q4 2025.
  • The company continues to have no revenue. Revenue was $0 in Q1 2026, as it was in the comparable historical periods provided.
  • Research and development spending is still minimal. R&D expense was only about $267.8 thousand in Q1 2026, which may indicate a very limited active development spend relative to the sector.
  • Interest income provided a small offset. The company earned about $318 thousand in interest and investment income during Q1 2026, but this was far too small to materially offset losses.
  • Debt is not the main issue right now. Repayment of debt was only about $3.6 million in Q1 2026, suggesting the capital structure is being driven more by equity funding than leverage.
  • Net loss widened dramatically. CNTN reported a Q1 2026 net loss of about $47.3 million, versus a $29.4 million loss in Q4 2025 and only $2.1 million in Q3 2025.
  • Operating expenses surged. SG&A jumped to about $36.6 million in Q1 2026 from $11.9 million in Q4 2025, driving the wider operating loss.
  • Other expenses were very large. The company recorded about $15.0 million of other expense, which further pushed losses higher.
  • Share count and dilution have risen significantly over time. Weighted average shares outstanding in Q1 2026 were about 207.7 million, up sharply from 32.0 million in Q4 2025 and just 2.6 million in Q1 2025, highlighting heavy dilution risk for existing shareholders.
  • Cash flow from investing was deeply negative. Investing activities used about $54.8 million in Q1 2026, largely due to “other investing activities,” which is a major use of cash and deserves close scrutiny.
  • Accumulated deficits remain large. Retained earnings were deeply negative at about $120.2 million, underscoring the company’s long operating history of losses.

Bottom line: Hillstream BioPharma’s Q1 2026 results show that it has secured liquidity, but not profitability. The company is still pre-revenue, losses are expanding, and dilution has been severe. For investors, the stock appears to be a financing story rather than a fundamentals-driven turnaround story at this point.

07/14/26 11:42 AM ETAI Generated. May Contain Errors.

Tharimmune Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Tharimmune's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Tharimmune's net income appears to be on an upward trend, with a most recent value of -$35.92 million in 2025, rising from -$2.42 million in 2020. The previous period was -$12.20 million in 2024. Find out what analysts predict for Tharimmune in the coming months.

Tharimmune's total operating income in 2025 was -$20.11 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $20.11 million

Over the last 5 years, Tharimmune's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Tharimmune's total liabilities were at $121.22 million at the end of 2025, a 4,921.6% increase from 2024, and a 2,921.2% increase since 2020.

In the past 5 years, Tharimmune's cash and equivalents has ranged from $4.36 thousand in 2021 to $17.03 million in 2025, and is currently $17.03 million as of their latest financial filing in 2025.

Over the last 5 years, Tharimmune's book value per share changed from -0.59 in 2020 to 11.35 in 2025, a change of -2,038.7%.


Related Companies

Financial statements for NASDAQ:THAR last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Confirm Your Name Before the Letter Goes Out
Americans who believe in real retirement protection are adding their names to a statement going out to Washing...
American Alternative | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
This Is How Financial Freedom Dies—And Most People Never See It Coming
While the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not b...
Priority Gold | Sponsoredtc pixel
The $5 company SpaceX can’t survive without
The investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...
Traders Agency | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel